These 6 deaths occurred in 1 patient who received tirzepatide at a dose of 5 mg, 2 patients who received tirzepatide at a dose of 10 mg, 2 patients (including the patient with presumptive Covid-19) who received tirzepatide at a dose of 15 mg, and 1 patient who received semaglutide
GI adverse eventsprimarily nausea, vomiting, and decreased appetitewere the most common, but were generally mild to moderate, consistent with early-phase GLP-1 or amylin agonist studies
Their anti-inflammatory properties also suggest benefits for chronic inflammatory conditions such as inflammatory bowel disease (IBD), with some clinical observations noting improvements in IBD symptoms
If you have chronic kidney disease, heart failure, liver disease, or take medications that affect electrolyte balance (such as diuretics, ACE inhibitors, or NSAIDs), discuss electrolyte supplementation with your doctor before starting